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See Article, pages 581–588Liver transplantation (LT) is in theory, the best treat-
ment for hepatocellular carcinoma (HCC) in cirrhotic
patients since it is a treatment that simultaneously deals
with the malignancy and its causes [1–3]. However, the
prognosis is directly related to the risk of HCC recur-
rence post-transplantation. The aim of preoperative
assessment in LT for HCC is therefore to detect existing
extra-hepatic metastases and predict extra-hepatic
micro-metastases that are responsible for recurrence,
graft loss and often, death of the patient.
Following the retrospective study by Bismuth et al.
[4], Mazzaferro et al. prospectively showed that careful
selection of patients with a single lesion of <5 cm or
three lesions each <3 cm, known as Milan criteria, has
resulted in a satisfactory balance between survival
(75%) at four years and recurrence rates (8%) [5]. The
validity of these criteria to predict recurrence-free sur-
vival after transplantation has been largely conﬁrmed
by several studies, which have demonstrated an overall
10-year survival ranging from 60% to 62% [6,7]. Hence,
survival of carefully selected patients is not diﬀerent
from survival of patients transplanted for non-malig-
nant indications [8]. Survival analysis by ITT clearly
suggested that resection or ablation in patients with
compensated cirrhosis are the only alternatives to liver0168-8278 2008 European Association for the Study of the Liver Publish.
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ing evidence that by limiting OLT only to patients fall-
ing within the Milan criteria might represent an unjust
penalty for selected patients beyond the Milan criteria
who could still have a favourable outcome with OLT.
In the United States, around 70% of cirrhotic patients
diagnosed with a HCC fall beyond the Milan criteria [3].
Survival analysis by ITT clearly suggested that regular
ultrasound screening of cirrhotic patients has permitted
detection of small unique nodule in Child-Pugh A cir-
rhotic patients in whom alternatives to transplantation
are possible. Second, liver transplantation will provide
a major survival gain in some patients with a HCC
who fall beyond the Milan criteria. Therefore, several
expansions of the Milan criteria have been proposed,
with the University of California, San Francisco
(UCSF) criteria described by Yao et al. being the most
investigated [9,10]. The UCSF criteria include a solitary
tumor of 6.5 cm or less, no more than three lesions with
the largest being 4.5 cm or less, and a total tumor diam-
eter 8 cm or less, without gross vascular invasion.
Unfortunately, the 5-year survival of patients beyond
Milan and within UCSF criteria ranges from 46% to
93% [9–12]. The resulting discrepancies between studies
which used UCSF criteria are related to the time of
application of the criteria (preoperative/radiological
and postoperative/pathological). Interestingly, a French
multicentric study of 479 patients demonstrated a higher
rate of understaging (48%) if UCSF criteria is used to
list patients for LT as compared to the understaging rate
of 34% when the Milan criteria is used [11]. Indeed, the
5-year survival of UCSF excluding Milan patients wased by Elsevier B V. . Open access under CC BY-NC-ND license.
E. Vibert, D. Samuel / Journal of Hepatology 49 (2008) 498–501 49945% compared to 60% in Milan patients [11]. Heteroge-
neous survival results in studies using UCSF criteria
emphasized that macroscopic parameters like size and
number would probably lose their eﬃcacy as surrogate
criteria to accurately predict the risk of tumor recur-
rence in comparison to tumoral volume exceeding the
Milan criteria.
Several studies have identiﬁed vascular invasion as
the strongest independent predictor factor of recurrence,
a pathological parameter also associated with other
poor prognostic factors like a poor diﬀerentiation of
the tumor, the presence of satellite nodules and a high
level of a-fetoprotein [6,13,14]. Unfortunately, except
for the latter, all these parameters are not easily avail-
able in the preoperative setting and particularly at
listing.
In 2003, based on the knowledge that HCC display
molecular alterations Marsh et al., classiﬁed HCC
according to the level of gene damage [15]. The goal of
this paper was to determine whether a panel of tumor
suppressor gene markers could be useful to predict
recurrence after LT for HCC. By microdissection,
non-neoplastic and neoplastic tissue samples for each
patient transplanted with a minimum of 5 years fol-
low-up were evaluated for informative status of 18 genes
located on microsatellite. Absence of microsatellites or
loss of heterozygoty (LOH) corresponded to the loss
of speciﬁc tumor suppressor genes such as APC,
CDKN2A, p53, and p34. Among 18 microsatellites
tested, 9 were signiﬁcantly correlated with the post-
transplant recurrence-free survival but none achieved
perfect discrimination alone. As a test, two types of sim-
pliﬁed panel of LOH that were the most accurate to pre-
dict recurrence were deﬁned. Thanks to this method and
with the help of an artiﬁcial neural network, an accurate
response was obtained in 91 of the 103 patients tested
(88%). The prediction of recurrence was accurate in
89% of cases.
Very recently, the same team has performed a similar
analysis on a larger cohort of patients transplanted for
HCC with more than 5 years of follow-up (183 patients
from Mount Sinai and University of Pittsburgh Medical
Center) [16]. In this study, a fractional allelic imbalance
(FAI) rate was calculated for each patient. This index
was deﬁned as the number of mutated markers divided
by the total number of informative markers. These
markers corresponded to the 9 microsatellites retrieved
as correlated with the post-transplant recurrence free
survival in their initial work [15]. Of note, all these 9
markers were not always informative, i.e present, in each
patient. The rate of mutation, i.e. FAI, was then depen-
dent on the number of informative markers. Hence, the
FAI represents a rough estimate of cumulative muta-
tional damage in tumor compared to non-neoplastic tis-
sue. FAI in the 9-gene panel ranged from 0% to 89%
(mean 31%). Among the patients tested, FAI and vascu-lar invasion were the most important independent fac-
tors of tumor-free survival. Patients with FAI > 40%
compared to those with FAI 6 20% have an increased
risk of recurrence by a factor of 19.5. Comparatively,
patients with macrovascular invasion compared with
those without vascular invasion have an increased risk
of recurrence of 5.9. This diﬀerence emphasized the
power of the FAI even comparatively with the more pre-
dictive pathological factor, vascular invasion [6,13,14].
Interestingly, a correlation with the Milan, UCSF crite-
ria and FAI has been described in this paper. For
patients outside the Milan criteria, the risk of recurrence
increased 4.5-fold compared to patients within, while a
FAI > 40% increased this risk 14-fold compared to
FAI 6 20%. For patients beyond UCSF criteria, the risk
of recurrence increased 6.0-fold compared to patients
within, while a FAI > 40% increased this risk 17.4-fold
compared to FAI 6 20%. In summary, this second
paper has demonstrated the much more powerful corre-
lation with recurrence of FAI compared with patholog-
ical data and macroscopic usual classiﬁcation.
Hence, the paper by Schwartz et al. which appears in
this issue of the Journal of Hepatology [17] focused on
the potential applicability of the FAI score in patients
beyond the Milan criteria with a favourable outcome
of LT. With the same methods of allelic imbalance anal-
ysis of HCC in transplanted patients, they have com-
pared tumoral and non-tumoral liver tissue for 18
genes markers to determine the FAI score. Statistically,
a FAI score of 0.27 was determined as the more reliable
cut-oﬀ value to predict recurrence or not. Univariate
and multivariate analysis of prognostic factors of recur-
rence were performed with 70 patients transplanted for
HCC with at least 5 years of follow-up. The FAI score
and macroscopic vascular invasion were the 2 indepen-
dent factors associated with recurrence. Interestingly,
FAI predicted recurrence in 86% compared to 76% using
Milan criteria. Unfortunately, the statistical signiﬁcance
if any of this diﬀerence was not reported in the paper.
Besides, it was probably due to the low rate of recur-
rence in Milan criteria (3/35) patients that this paper
focused on patients beyond Milan criteria. In the sub-
group of patients beyond Milan criteria, the same pre-
dictive factors of recurrence were conﬁrmed but, in
this group, a FAIP 0.27 was predictive of recurrence
with a sensitivity of 83%, a speciﬁcity of 91% and overall
accuracy of 89%. Thus, this paper emphasized the utility
of FAI analysis only in patients beyond the Milan crite-
ria. Besides, among the 35 patients within the Milan cri-
teria, 4 of 6 of those who were predicted to have
recurrence according to FAI did not.
Even if it was useful in patients beyond Milan crite-
ria, the major drawback of this technique was the neces-
sity of full pathological examination. To date, all papers
that explored evaluation of FAI have used surgical spec-
imens to predict recurrence. As underlined by Marsh
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olating this work to the preoperative area were: (1) All
tumors are not recognized preoperatively. (2) It is not
practical or feasible to biopsy all detected tumors multi-
ple times in the preoperative setting. Indeed, Pawlik
et al. have analyzed the concordance between histologi-
cal data using preoperative needle core biopsy (14–18
gauges) of HCC and ﬁnal pathological analysis [18]. In
this study that included 120 patients, preoperative
biopsy misclassiﬁed tumor grade in 55% of cases. The
poor diagnostic accuracy of preoperative biopsy was
related to the very heterogeneous pathological and
molecular alteration of HCC, even in small tumors. Inci-
dence of grading heterogeneity was reported in 18–46%
[19–21] of HCC smaller than 2 cm and 36–43% in 2–
3 cm nodules [19,21]. This heterogeneity was due to
sequential development of HCC often displaying the
nodule-in-nodule pattern where a subpopulation with
a more malignant potential develops in a pre-existing
nodule. Interestingly, as grading heterogeneity, molecu-
lar alterations, notably mutation of p53 and b-catenin,
were also retrieved inside small HCCs [21].
As reported in the paper by Schwartz et al. [17], the
value of FAI was dependent on the number of mutated
genes to the total number of informative genes. It was
the variability of informative gene numbers that has
imposed the calculation of an index. Indeed, a recent
paper has focused on the genetic diversity of human
HCC [22]. In this work, a transcriptome analysis with
genotype and phenotype correlation has been performed
in a surgical series of 120 HCCs and 3 hepatocellular
adenomas. The transcriptome analysis identiﬁed 6 sub-
groups (G1–G6) of HCCs associated with clinical and
genetic characteristics. HCC of G1 and G2 group were
associated with HBV infection. G3 HCC mainly
included p53 mutation but without HBV infection. G4
HCC was a heterogeneous group of HCCs.G5 and G6
were highly related to b-catenin activation. Interestingly,
HCC groups G1 to G3 were associated with a high rate
of chromosomal instability in contrast to G5 and G6
where no chromosome deletion, then no LOH was iden-
tiﬁed. Hence, claims that FAI, largely correlated with
LOH, in these subgroups of HCC is questionable and
emphasized the fact that the FAI ratio is only a rough
measure of cumulative mutational damage. It should
be emphasized that the correlation of FAI and viral hep-
atitis was not assessed in the paper by Schwartz and
colleagues.
Despite these limitations, FAI represents a promising
new tool to predict recurrence after LT, even if it is only
of beneﬁt postoperatively in patients falling beyond the
Milan criteria. In the post-transplant setting, FAI could
provide useful information to adapt immunosuppressive
therapy and adjuvant chemotherapy thus attenuating
the risk of recurrence [23]. In the pre-transplant setting,
the application of molecular markers needs further eval-uation before being used as selection criteria for liver
transplantation.
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